Patents by Inventor Frederic de Sauvage

Frederic de Sauvage has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patched-2 antibodies
    Publication number: 20070049730
    Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, antibodies, vectors and host cells expressing, immunoadhesins, agonists and antagonists to patched-2.
    Type: Application
    Filed: October 4, 2006
    Publication date: March 1, 2007
    Inventors: Frederic de Sauvage, David Carpenter
  • ANTI-FUSED ANTIBODIES
    Publication number: 20070042415
    Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing, immunoadhesins, agonists and antagonists (including antibodies) to human & vertebrate fused.
    Type: Application
    Filed: September 29, 2006
    Publication date: February 22, 2007
    Inventors: Frederic de Sauvage, Arnon Rosenthal, Maximilien Murone
  • Compositions and methods for the treatment of tumor of hematopoietic origin
    Publication number: 20060251662
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: May 4, 2006
    Publication date: November 9, 2006
    Inventors: Wesley Chang, Frederic de Sauvage, Dan Eaton, Allen Ebens, Gretchen Frantz, Jo-Anne Hongo, Hartmut Koeppen, Andrew Polson, Victoria Smith
  • GFRalpha3 and its uses
    Publication number: 20060216289
    Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing, and immunoadhesions and antibodies to mammalian GFR?3, a novel ?-subunit receptor of the GDNF (i.e. GFR) receptor family. It further relates to an assay for measuring activation of an ?-subunit receptor by detecting tyrosine kinase receptor activation (i.e., autophosphorylation) or other activities related to ligand-induced ?-subunit receptor homo-dimerization or homo-oligomerization.
    Type: Application
    Filed: June 6, 2006
    Publication date: September 28, 2006
    Inventors: Frederic de Sauvage, Robert Klein, Heidi Phillips, Arnon Rosenthal
  • Compositions and methods for the treatment of tumor of hematopoietic origin
    Publication number: 20050238650
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: November 16, 2004
    Publication date: October 27, 2005
    Inventors: Craig Crowley, Frederic de Sauvage, Dan Eaton, Allen Ebens, Andrew Polson, Victoria Smith
  • Compositions and methods for the treatment of tumor of hematopoietic origin
    Publication number: 20050226869
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: December 21, 2004
    Publication date: October 13, 2005
    Inventors: Wesley Chang, Dan Eaton, Allen Ebens, Frederic de Sauvage, Gretchen Frantz, Jo-Anne Hongo, Hartmut Koeppen, Andrew Polson, Victoria Smith
  • GFRalpha3 and its uses
    Publication number: 20050221330
    Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing, and immunoadhesions and antibodies to mammalian GFR?3, a novel ?-subunit receptor of the GDNF (i.e. GFR) receptor family. It further relates to an assay for measuring activation of an ?-subunit receptor by detecting tyrosine kinase receptor activation (i.e., autophosphorylation) or other activities related to ligand-induced ?-subunit receptor homo-dimerization or homo-oligomerization.
    Type: Application
    Filed: July 16, 2003
    Publication date: October 6, 2005
    Inventors: Frederic de Sauvage, Robert Klein, Heidi Phillips, Arnon Rosenthal
  • Human suppressor of fused
    Publication number: 20050196814
    Abstract: The present invention is directed to novel polypeptides having homology to a polypeptide suppressor of the Drosophila melanogaster fused protein and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Application
    Filed: April 1, 2005
    Publication date: September 8, 2005
    Inventors: Frederic de Sauvage, Maximilien Murone, Arnon Rosenthal, Donna Stone, Austin Gurney, William Wood
  • Anti-fused antibodies
    Publication number: 20040102610
    Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing, immunoadhesins, agonists and antagonists (including antibodies) to human & vertebrate fused.
    Type: Application
    Filed: June 17, 2002
    Publication date: May 27, 2004
    Applicant: Genentech, Inc.
    Inventors: Frederic de Sauvage, Arnon Rosenthal, Maximilien Murone
  • Nucleic acid encoding patched-2
    Patent number: 6709838
    Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, antibodies, vectors and host cells expressing, immunoadhesins, agonists and antagonists to patched-2.
    Type: Grant
    Filed: April 15, 1998
    Date of Patent: March 23, 2004
    Assignee: Genentech, Inc.
    Inventors: Frederic de Sauvage, David A. Carpenter
  • Compositions and methods for treatment of cancer
    Publication number: 20030215457
    Abstract: The present invention concerns compositions and methods for the treatment of disorders characterized by the over-expression of an LIV-1. More specifically, the compositions include DNA and amino acid sequences of an LIV-1, antibodies to an LIV-1, and methods for the treatment of a mammal susceptible to or diagnosed with cancer wherein an LIV-1 is overexpressed.
    Type: Application
    Filed: October 24, 2002
    Publication date: November 20, 2003
    Inventors: Frederic de Sauvage, Audrey Goddard, Austin L. Gurney, Jo-Anne S. Hongo
  • Fused polypeptides
    Patent number: 6531579
    Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing, immunoadhesins, agonists and antagonists to human & vertebrate fused.
    Type: Grant
    Filed: February 25, 1999
    Date of Patent: March 11, 2003
    Assignee: Genentech, Inc.
    Inventors: Frederic de Sauvage, Arnon Rosenthal
  • Fused polypeptides
    Patent number: 6451977
    Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptide, vectors and host cells expressing, immunoadhesins, agonists and antagonists to human & vertebrate fused.
    Type: Grant
    Filed: September 3, 1999
    Date of Patent: September 17, 2002
    Assignee: Genentech, Inc.
    Inventors: Frederic de Sauvage, Arnon Rosenthal, Maximilien Murone
  • Patched-2
    Patent number: 6348575
    Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, antibodies, vectors and host cells expressing, immunoadhesins, agonists and antagonists to patched-2.
    Type: Grant
    Filed: April 15, 1999
    Date of Patent: February 19, 2002
    Assignee: Genentech, Inc.
    Inventors: Frederic de Sauvage, David A. Carpenter
  • Fused
    Patent number: 6022708
    Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing, immunoadhesins, agonists and antagonists to human & vertebrate fused.
    Type: Grant
    Filed: February 26, 1998
    Date of Patent: February 8, 2000
    Assignee: Genentech, Inc.
    Inventors: Frederic de Sauvage, Arnon Rosenthal